Dutasteride and RU58841 are both used by hair-loss communities but work through completely different mechanisms and have vastly different evidence bases. Dutasteride is an FDA-approved prescription drug with decades of clinical trial data, and the FDA label reports a median serum DHT decrease of 94% at 1 year on 0.5 mg/day. It is approved for bph/">benign prostatic hyperplasia only, so its use for hair loss is off-label. RU58841 is an experimental non-steroidal antiandrogen that acts as an androgen receptor (AR) blocker directly at the hair follicle. RU58841 has never completed Phase III clinical trials, has no established safety profile, no manufacturing quality standards, and is not legally available as a pharmaceutical product in the United States.
⚠️ Important: RU58841 is not FDA-approved, not regulated as a drug, and is sold as a “research chemical.” Its safety profile in humans is unknown and it has no quality control standards. This article provides factual information for educational purposes only. Dutasteride.com does not endorse the use of unregulated research chemicals.
Mechanism of Action: How They Differ
Understanding the fundamental difference in mechanism is critical to evaluating these two approaches:
| Property | Dutasteride | RU58841 |
|---|---|---|
| Mechanism | 5-alpha reductase inhibitor: blocks DHT production | Androgen receptor antagonist: blocks DHT from binding to follicle receptors |
| Target | Enzymatic (systemic) | Receptor (topical/local) |
| Route | Oral | Topical (self-compounded solution) |
| Systemic absorption | Significant (oral bioavailability) | Unknown / theoretically low (topical) |
| Serum DHT reduction | ~94% at 1 year on 0.5 mg/day (FDA label) | Not a 5-alpha reductase inhibitor, so no DHT reduction by that mechanism |
| Evidence base | Multiple Phase III RCTs, FDA-approved | No published human efficacy or safety trial. The primary published work is a 1994 in vitro and animal characterization |
| FDA approval | Yes (BPH); off-label (hair loss) | No |
| Legal status (US) | Prescription drug | Sold as a research chemical, not for human use, and not an approved drug |
| Quality control | FDA-regulated pharmaceutical manufacturing | None (varies by vendor) |
| Long-term safety data | 4-year REDUCE trial (8,231 men) | Unknown, with no published long-term human data |
The Theoretical Appeal of RU58841
RU58841 appeals to the hair-loss community for a specific reason: because it acts at the androgen receptor locally at the follicle rather than reducing systemic DHT production, it theoretically avoids the sexual side effects associated with systemic DHT suppression (which finasteride and dutasteride cause). If DHT levels in the bloodstream remain unchanged, sexual function is theoretically preserved while scalp follicles are protected.
This is a legitimate pharmacological hypothesis. However, “theoretical” is the operative word. RU58841 was characterized in the early 1990s in in vitro and animal work (Battmann and colleagues, 1994) and was never carried through to a published human efficacy trial or an approval submission anywhere. No published trial has confirmed this benefit-risk profile in humans, and no regulator has reviewed the compound for human use.
Key Risks of RU58841
- Unknown safety profile: there is no published human safety data. Carcinogenicity, mutagenicity, and long-term endocrine effects in humans are undocumented.
- No manufacturing standards: RU58841 is sold by research chemical vendors with varying purity. Users cannot verify what they are actually applying to their scalp.
- Systemic absorption is not zero: applying a compound to the scalp does not guarantee that none of it reaches the bloodstream. RU58841’s absorption and systemic exposure in humans have not been studied, so the claim that it acts only locally is an assumption, not a finding.
- Potential instability: RU58841 is chemically unstable in solution and may degrade rapidly, particularly when dissolved in ethanol at room temperature. Degradation products are unknown and unstudied.
- No legal protection: If you experience an adverse effect from an unregulated research chemical, there is no legal recourse against the vendor.
Which Is Better?
For patients seeking an evidence-based treatment with a known safety profile, dutasteride is the better documented choice. It has decades of clinical data, FDA approval for BPH, and pharmaceutical-grade manufacturing. The sexual side effect concern is real and quantified. In the pooled placebo-controlled BPH trials in the FDA label, over the first 6 months, impotence was reported by 4.7% of men on dutasteride versus 1.7% on placebo, decreased libido by 3.0% versus 1.4%, and ejaculation disorders by 1.4% versus 0.5%. The label states that the incidence of these reactions decreased with increased duration of treatment.
For patients who experienced dutasteride or finasteride side effects and want a local option, topical dutasteride (currently in clinical trials) represents a more scientifically grounded approach than RU58841, as it uses the same FDA-approved molecule but aims for local action with reduced systemic exposure. Topical dutasteride information.
Sources
- Battmann T, et al. RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. J Steroid Biochem Mol Biol. 1994;48(1):55-60. PubMed
- Andriole GL, et al. Effect of dutasteride on the risk of prostate cancer (REDUCE trial). N Engl J Med. 2010;362(13):1192-202. PubMed
- FDA. Avodart (dutasteride) prescribing information. accessdata.fda.gov